Genmab A/S - American Depositary Shares (NQ:GMAB)

55.23 +0.31 (+0.57%)

Delayed Quote Updated: 2:38 PM EST, Nov 3, 2026 Add to My Watchlist

Price and Volume

Volume	1,918,842
Open	55.46
Bid (Size)	55.23 (200)
Ask (Size)	55.25 (400)
Prev. Close	54.92
Today's Range	55.18 - 56.50
52wk Range	23.62 - 59.97
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches ↗

October 28, 2026

Genmab A/S (NASDAQ:GMAB) said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the...

Via MarketBeat

Top US Stock Movers in Today's Session ↗

October 28, 2026

Via Chartmill

Performance

52-Week Range 7.9% below 52-week high

55.23

23.6252W Low 59.9752W High

1 Week 7.9% below 1-week high

43.981W Low 59.971W High

Genmab A/S - American Depositary Shares (GMAB) traded between $23.62 and $59.97 over the past 52 weeks and last traded at $55.23, 7.9% below its 52-week high. Over the past week it ranged between $43.98 and $59.97.

Past 12 Months

+23.7%

+43.5%

+92.6%

+104.3%

+73.6%

+92.4%

1W +$10.56

1M +$16.76

3M +$26.55

6M +$28.20

YTD +$23.41

1Y +$26.52

GMAB was +92.4% over the past year, +104.3% over six months, +73.6% year to date, +23.7% in the last week.

12 Months vs Market

GMAB

+92.4%

DIA

+9.3%

SPY

+10.5%

QQQ

+8.4%

IWM

+14.3%

Over the past 12 months GMAB returned +92.4% versus DIA (Dow) +9.3%, SPY (S&P 500) +10.5%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.3%.

Volume & Liquidity 0.48× 3-mo avg

Today 1,918,842 3-mo avg 4.0M

10.7M

6.5M

4.0M

3.0M

YTD

2.5M

2.3M

GMAB most recently traded 1,918,842 shares against a 3-month average daily volume of 4.0M.

More News

US Top Movers: Biggest Gainers and Decliners in Today's Session ↗

October 28, 2026

Via Chartmill

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

October 28, 2026

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Eyes Breakout as Technical Strength Builds ↗

October 20, 2026

Via Chartmill

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

October 26, 2026

Via FinancialNewsMedia

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

October 26, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

October 25, 2026

From Genmab A/S

Via Business Wire

Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup ↗

August 01, 2026

Via Chartmill

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

October 23, 2026

From Genmab A/S

Via Business Wire

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

October 05, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

October 03, 2026

From Genmab A/S

Via Business Wire

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 ↗

September 26, 2026

Via MarketBeat

Genmab (GMAB) Q2 2026 Earnings Call Transcript ↗

August 06, 2026

Via The Motley Fool

Genmab A/S Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

July 23, 2026

From Genmab A/S and AbbVie

Via Business Wire

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

July 06, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

June 29, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

June 13, 2026

From Genmab A/S

Via Business Wire

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

June 11, 2026

From Genmab

Via Business Wire

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

May 21, 2026

From Genmab A/S

Via Business Wire

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

April 13, 2026

From Genmab A/S

Via Business Wire

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Via The Motley Fool

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

Via MarketMinute

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 55.23

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 11/03/26 02:38 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.